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Abstract
Background: Inflammation in the early stages of sepsis is governed by the innate immune response. Costimulatory
molecules are a receptor/ligand class of molecules capable of regulation of inflammation in innate immunity via
macrophage/neutrophil contact. We recently described that CD80/86 ligation is required for maximal macrophage
activation and CD80/86
2/2 mice display reduced mortality and inflammatory cytokine production after cecal ligation and
puncture (CLP). However, these data also demonstrate differential regulation of CD80 and CD86 expression in sepsis,
suggesting a divergent role for these receptors. Therefore, the goal of this study was to determine the individual
contribution of CD80/86 family members in regulating inflammation in sepsis.
Methodology/Principal Findings: CD80
2/2 mice had improved survival after CLP when compared to WT or CD86
2/2 mice.
This was associated with preferential attenuation of inflammatory cytokine production in CD80
2/2 mice. Results were
confirmed with pharmacologic blockade, with anti-CD80 mAb rescuing mice when administered before or after CLP. In vitro,
activation of macrophages with neutrophil lipid rafts caused selective disassociation of IRAK-M, a negative regulator of NF-
kB signaling from CD80; providing a mechanism for preferential regulation of cytokine production by CD80. Finally, in
humans, upregulation of CD80 and loss of constitutive CD86 expression on monocytes was associated with higher severity
of illness and inflammation confirming the findings in our mouse model.
Conclusions: In conclusion, our data describe a differential role for CD80 and CD86 in regulation of inflammation in the
innate immune response to sepsis. Future therapeutic strategies for blockade of the CD80/86 system in sepsis should focus
on direct inhibition of CD80.
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Introduction
Sepsis, the systemic inflammatory response to infection (SIRS),
is a devastating condition affecting nearly 750,000 people/year
and resulting in over $17billion/year in health care expenditure
[1,2]. Currently, sepsis is the leading cause of death in the ICU
and 10
th leading cause of death overall [3]. However, in spite of
maximal supportive care and appropriate antimicrobial therapy,
mortality remains in excess of 25% underscoring the need for
better adjuvant therapies [1,2].
The innate immune response forms the corner stone of
regulation of inflammation and pathogen control in sepsis. This
is characterized by an initial burst of pro-inflammatory cytokines,
such as IL-6, TNF-a and IL-1b, which in controlled settings, can
recapitulate many of the clinical findings of sepsis. However,
numerous trials have shown that neutralization of any of these
cytokines individually has little to no impact on survival [4,5]. One
potential reason for their failure is the redundant and overlapping
nature of many of these individual cytokines [6]. For example,
while neutralization of ether TNF-a or IL-1b has little effect on
mortality in humans or in mice subjected to lethal polymicrobial
sepsis via Cecal Ligation and Puncture (CLP), combined
neutralization does improve survival in CLP [7,8,9]. As a result,
many investigators have begun to target receptors/mediators
capable of simultaneously regulating numerous pro-inflammatory
cytokines.
Costimulatory molecules are one class of receptors which have
recently been implicated as fulfilling this role in the innate immune
response [10,11,12,13]. CD80 and CD86 represent one class of
costimulatory receptors. They are stimulated via CD28 while
CTLA4 serves as both a stoichiometric inhibitor of CD28-CD80/
86 engagement as well as serving to directly induce immunosuppres-
sive signals within dendritic cells [14,15,16]. Given the high degree of
homology and functional overlap between CD80 and CD86, studies
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common ligand (CD28) or to use a CD80/CD86
2/2 mouse.
While a large body of evidence points to a critical role for the
CD28-CD80/86 system in regulating inflammation in autoim-
mune disease and graft vs. host disease in the adaptive immune
response, our group and others have now described a similar role
in the innate immune response. Specifically, neutrophils express-
ing CD28 activate macrophages in a contact dependent manner
via engagement of CD80/86 [17]. In turn, CD80/86 signal via
NF-kB to induce numerous cytokines, most notable IL-6 [14]. In
vivo, deletion or blockade of CD80/86 improves survival and
attenuates pro-inflammatory cytokine production in CLP [18].
However, these studies also demonstrated that monocyte
expression of CD80 and CD86 were differentially regulated in
sepsis [18]. Specifically, sepsis was associated with an increase in
CD80 expression, while there appeared to be a downregulation of
constitutive CD86 expression. Further, recent studies suggest
CD80 and CD86 have differential regulation in the inflammatory
response in vivo in diseases regulated by the adaptive immune
response, including allergic rhinitis and graft rejection [19,20].
Combined, these data imply a possible differential role for CD80
and CD86 in regulating mortality and inflammation in the innate
immune response as well. Consequently, the goals of this study
were to determine the individual contribution of CD28, CD80 and
CD86 to the inflammatory response in murine sepsis, and to better
correlate expression of these molecules with outcome in humans
with sepsis and septic shock.
Methods
Ethics Statement
All animal studies were approved by the New York University
and Oregon Health and Sciences University Institutional Animal
Care & Use Committee (IACUC). For human studies, the protocol
was approved by the Oregon Health and Sciences University
Institution Review Board and written consent was obtained from
all subjects or their designated representative.
Mice
6–8 week old female C57BL/6 (WT), CD28
2/2, CD80
2/2 and
CD86
2/2 mice were purchased from Jackson Labs. All mice were
on a C57BL/6 background. Mice were allowed to acclimatize for
1 week prior to use. All mice were housed in SPF facility. Cecal
Ligation and Puncture. CLP was performed as previously
described [10,11,12,13]. Briefly, mice were anesthetized with
2.5% isoflourane and underwent CLP with a 19 gauge needle.
Mice received 1 cc 0.9% saline subcutaneously for resuscitation.
At specified times, the mice were used to collect plasma,
bronchoalveolar lavage (BAL) and peritoneal lavage (PL) (3 cc)
as previously described [10]. For survival experiments, mice were
monitored for a total of 14 days. For antibody inhibition, 250 mg
of a-CD80 (16-10A1; hybridoma from ATCC) or a-CD86 (GL-1,
hybridoma from ATCC) were injected ip 4 hrs prior to or 2 hrs
post -surgery. Rat IgG (Biolegend) was used as an antibody control
and PBS as a vehicle control. As there was no difference between
the 2, these groups were combined where indicated. IL-6, IL-10,
IL-12p40, and IL-1b were determined by commercially available
immunoassays (R&D systems) and performed according to the
manufacturers’ specifications.
Flow Cytometry. Flow cytometry was performed as
previously described [18]. Whole blood or peritoneal lavage were
collected and 1610
6 cells were then labeled with the following
antibodies: CD80, CD86, CD14 at optimal concentration for
45 min in the dark.Red bloodcells were lysed with RBC lysis buffer
then the cells were fixed with 0.1%paraformaldehyde and analyzed
on a BD LSRII 8-color analyzer with FloJo software. All reagents
were purchased from BDPharmigen. BD compensation beads were
used to calibrate the instrument before each use. PMNs were
identified by FSC/SSC characteristics; mononuclear cells by FSC/
SSC, CD11b
+ and CD14
+, Isotype antibody labeled cells were used
to control for nonspecific staining.
Purification of PMN and preparation of Lipid rafts. Hu-
man PMNs and lipids rafts were obtained from healthy volunteers
and prepared as previously described [17]. Briefly, PMN were
isolated from whole blood by Ficoll-Hypaque (Amersham
Pharmacia) sedimentation. PMN (.99.9% granulocytes, .95%
PMNs) were separated by dextran sedimentation (3% dextran in
0.9% NaCl solution @ 1 g,30 min).PMNwereactivatedby100 ng/
ml LPS (Sigma). For Detergent Resistant Membrane (DRM)/Lipid
raft isolation, cells were lysed on ice with 200 ml of 1% Triton X-100
and gently mixed with an equal volume of 80% sucrose (wt/vol) and
placed in the bottom of a Beckman centrifuge tube. The sample was
then overlaid with 1000 ml of 30% sucrose and 600 mlo f5 %s u c r o s e
spun for 16–24 h at 44,000 rpm at 4uC in a Beckman TLS 55 swing
rotor using Beckman OPTIMA TLX Ultracentrifuge. 200 ml
fractions were harvested serially from the top of the gradient. The
DRM/raft fraction was obtained in fractions 1–4.
Immunoprecipitation
Human monocytes derived macrophages were isolated from
healthy volunteers and prepared as previously described [17].Cells
harvested and washed with PBS 63 and total cell lysate prepared
using NP40 lysis buffer as previously described. Lysate (normalized
for equal protein content) was then incubated with 10 mg
antibodies to CD80 or CD86. One ml of extract was then
incubated with end-over-end mixing for 2 hours at 4uC. Fifty mlo f
Protein A/G Sepharose (Santa Cruz Biotech) were washed with
1 ml of lysis buffer. This was repeated 3 times and then excess
buffer was carefully removed. After the 2 hour incubation, the
washed Protein A/G Sepharose was added to the immunopre-
cipitates and mixed for 1 hour at 4uC. The immunoprecipitates
were washed 3X with 1 ml of lysis buffer. Samples then assayed by
Western blot as previously described.
Immunofluorescence Confocal Laser Microscopy
Cells were attached to poly-L-Lysine-coated coverslips and fixed
in 4% paraformaldehyde/PBS followed by acetone/methanol
(1:1, vol./vol.). After blocking in non-specific IgG for 30 minutes,
they were incubated with primary antibody (1:1000) over night.
Following washing in PBS, cells were incubated with appropriate
secondary antibodies containing Alexa-Fluor-labeled 488, 563, or
633 IgG (H+L) antibodies (Molecular Probes, OR) (1:500) for 30
minutes as previously described [17]. After final wash, samples
were mounted with VectraShield mounting medium (Vector
Laboratories) and images were obtained and quantified by Leica
TCS NT imaging software. Images were processed with Photo-
shop (Adobe Systems, Mountain View, CA).
Human studies
All patients meeting SCCM/ACCP criteria for sepsis in the first
24 hrs of ICU stay were eligible for inclusion [21]. Patients were
excluded for the following reasons; presence of a Do Not
Resuscitate order or decision to institute comfort care measures,
Hgb,7 g/dl or the presence of active bleeding requiring more
than 2 units of packed red blood cells. After obtaining informed
consent, 25 cc of blood was collected into glass (serum) or EDTA
coated tubes (platelet poor plasma) within the first 24 hrs of
admission. Clinical data including APACHE II scores were
CD80 and CD86 in Sepsis
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28 days or until death or hospital discharge.
Statistics
Survival was analyzed by Kaplan-Meier analysis. All compar-
isons between groups were performed by Mann-Whitney t-test (2
groups) or ANOVA (multiple groups). Correlations were made
with Spearman’s test. All statistics were done with GraphPad
Prism 5.0 (San Diego, CA).
Results
We first wished to establish that CD28 was serving as the
predominant ligand for CD80 or CD86 engagement in sepsis.
CD28
2/2 mice had improved overall and median survival
compared to WT mice after CLP (Figure 1A). Improvement in
survival was associated with attenuation in plasma IL-12 and IL-6,
with little change in IL-10 (Figure 1B) or IL-1b (not shown) 18 hrs
after CLP. IFN-c, another cytokine regulated by CD28, was
undetectable in both groups of animals [14]. We observed similar
results in the lung (not shown), suggesting CD28 regulates
inflammation in multiple tissue compartments. Together suggest-
ing CD28, through either CD80 or CD86 is capable of mediating
the inflammatory response and lethality of polymicrobial sepsis.
We next sought to determine the relative contributions of CD80
and CD86 to mortality and inflammatory cytokine production in
polymicrobial sepsis. Interestingly, CD80
2/2 mice had a marked
improvement in median and overall survival compared to WT
(p,0.001) and CD86
2/2 mice (p=0.01). In contrast, there was
only a modest benefit observed in median survival in CD86
2/2
mice compared to WT controls (median survival 42 vs. 25 hrs;
p=0.002) with no change in absolute survival (20% vs. 5%;
p.0.2) (Figure 2A). This was associated with a preferential
attenuation of plasma IL-6 and IL-1b in CD80
2/2 mice
compared to WT or CD86
2/2 mice (Figure 2B). We observed
similar results in BALF (Figure 2C). However, in peritoneal lavage,
IL-10 was preferentially attenuated in CD86
2/2 mice (Figure 2D).
This being more consistent with some reports describing a
preferential role for CD86 in regulating IL-10 production and is
consistent with our previous description of differential CD86
expression in various tissue compartments in CLP, with increased
levels of CD86 found in PL compared to blood [22].
We next used a pharmacologic approach to confirm the results
with our knockout mice. Pre-treatment with anti-CD80 mAB
significantly improved survival compared to either control IgG or
anti-CD86 mAB (Figure 3A). Similar to observations with
knockout mice, anti-CD86 modestly improved median survival
compared to controls (42 vs. 18 hrs; p=0.03), yet when combined
with anti-CD80, antagonized the beneficial effects of anti-CD80.
Anti-CD80 also proved to be an effective rescue therapy as post-
CLP administration significantly improved survival compared to
controls (Figure 3B). Similar to what we observed with pre-CLP
therapy, addition of CD86 blockade antagonized the effects of
anti-CD80 therapy.
We next sought to determine a potential mechanism for CD80
regulation of inflammation. Prior studies suggest CD28 induces
NF-kB induction via CD80 and CD86 [14]. At baseline,
Interleukin-1 receptor associated kinase-M (IRAK-M), a negative
regulator of NF-kB signaling, was associated with CD80 as
opposed to CD86. Upon addition of neutrophil lipid rafts,
Figure 1. CD28
2/2 mice are protected from lethality of polymicrobial sepsis. Panel A-WT (n=15) and CD28
2/2 (N=15) underwent CLP
and were monitored for survival. Panel B. WT and CD28
2/2 mice underwent CLP and were sacrificed at 18 hrs and plasma collected for cytokine
analysis via commercially available ELISA. N=5/group.
doi:10.1371/journal.pone.0006600.g001
CD80 and CD86 in Sepsis
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6600previously reported by our lab as a source of CD28 and stimulator
of macrophages in vitro and in vivo [17], the association of CD80
with IRAK-M at 1 hr was abolished (Figure 4A). In contrast, there
was an increase in association of CD86 and IRAK-M 1 hr after
the addition of lipid rafts. The interaction between CD80 and
IRAK-M was confirmed by immunofluorescent microscopy,
Figure 2. CD80 preferentially control lethality and inflammation in CLP. Panel A-WT (n=20) and CD80
2/2 (N=15) and CD86
2/2 (N=15)
underwent CLP and were monitored for survival. P,0.04 (CD80
2/2 vs. CD86
2/2), p,0.001 (CD80
2/2 vs. WT) and p,0.01 (WT vs. CD86
2/2). Panel B–
D. WT and CD80
2/2 and CD86
2/2 mice underwent CLP and were sacrificed at 18 hrs and plasma (Panel B), BALF (Panel C) and PL (Panel D) were
collected for cytokine analysis via commercially available ELISA. N=8–10 mice/group. +=,0.1, *=,0.05.
doi:10.1371/journal.pone.0006600.g002
Figure 3. CD80 blockade preferentially improves survival after CLP. Panel A-WT C57BL/6 mice were administered either 250 mg anti-CD80,
anti -CD86 or both 4 hrs prior to CLP and monitored for survival (n=10/group). Data from anti -CD80/86 has been published previously [18]. P=0.002
for anti-CD80 vs. control. Panel B-WT mice were administered control IgG or anti -CD80 or anti -CD80/86 (250 mg each) 2 hrs post-CLP and
monitored for survival (n=10/group). p=0.002 for anti-CD80 vs. control.
doi:10.1371/journal.pone.0006600.g003
CD80 and CD86 in Sepsis
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6600which demonstrated that at baseline, there was significant co-
localization of CD80 and IRAK-M. (Figure 4B, Row 1) After
addition of PMN lipid rafts, while there was no change in the
amount of CD80 and IRAK-M, by 4 hrs (Figure 4B Row 3), the
vast majority of CD80 was no longer associated with IRAK-M
(Figure 4B Row 3). In contrast, the amount of IRAK-M associated
with CD86 actually increased after stimulation (Figure 4B Row 5).
Finally, we confirmed that IRAK-M did indeed associate with
TRAF-6 in our system and that there was a slight decrease in this
association with PMN lipid raft stimulation providing another
mechanism for de-repression of macrophages by PMN contact
(Figure 4C).
Finally, we sought to expand our previously reported data and
determine whether differential expression of CD80 and CD86
occurred in humans with sepsis and if expression levels could serve
as biomarkers for outcome [18]. Clinical characteristics of enrolled
subjects are presented in Table 1. CD80, was upregulated on
circulating monocytes in septic humans, with higher levels
associated with both the presence of shock (Figure 5A) and
correlating with overall severity of illness as determined by SOFA
score (Figure 5B). There was no association between levels of CD80
and survival or cytokine levels. A relatively protective role for CD86
was supported by the presence of higher levels of expression on
circulating monocytes in survivors and those with negative blood
cultures (Figure 5C and E). Higher levels of CD86 also correlated
with ICU free days (Figure 5D). Finally, levels of CD86 correlated
inversely with circulating levels of IL-10 and IL-6 (Figure 5F and G)
suggesting a relatively anti-inflammatory role for CD86 in vivo.
Discussion
One of the major findings of this paper is the observation of
improved survival in CD28
2/2 mice after CLP. The ability of
CD28 to regulate inflammation in the innate immune response to
sepsis is consistent with prior reports documenting CD28
expression on PMNs and the ability of CD28, either soluble or
in PMN lipid rafts, to induce NF-kB and pro-inflammatory
cytokine production via CD80/CD86 [14,17,23]. Our results are
also consistent with earlier reports suggesting an important role for
Figure 4. PMN membranes disassociate IRAK-M from CD80. Macrophages were treated with PMN lipid rafts for various times Panel A. Co-IP
demonstrates CD80 binds IRAK-M in resting PMA differentiated THP-1 macrophages, lane 1. One hour after lipid raft treatment IRAK-M disassociates
from CD80, lane 2. CD86 binds little IRAK-M in resting macrophages, lane3. There is association of IRAK-M with CD86 one hour after lipid raft addition,
lane4. Panel B. Confocal microscopy of resting monocyte derived macrophages at baseline (Row 1,4) or stimulated with PMN lipid rafts for 1 hr (Row
2,5) or 4 hrs (Row 3,6). IRAK-M (Red), CD80 (Left Panel-green) or CD86 (Right Panel-green) and co-localization (Yellow). Nucelar stain with DAPI (blue).
Panel C. PMA differentiated THP-1 macrophages were stimulated with PMN lipids rafts and harvested at the designated time point. Whole cell
extracts were IP for TRAF-6 and blotted for IRAK-M. All lanes (panel A and C) were normalized for protein prior to immunoprecipitation.
doi:10.1371/journal.pone.0006600.g004
Table 1. Clinical Characteristics of enrolled subjects. Absolute
values are presented are Mean6SEM.
Septic Subjects (n=40)
Age (years) 56.862.43
Sex (% Female) 35%
APACHE II 17.161.04
SOFA 6.760.7
Mechanical Ventilation (%) 42.5
Vasopressors (%) 65
Bactermia (%) 37.5
28 Day Mortality (%) 17.5
doi:10.1371/journal.pone.0006600.t001
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the role for CD28 in mediating toxic shock in mice [6,24]. Finally,
these data support the recent observations of lethal cytokine storm
in with administration of an agonist CD28 antibody in humans
[25]. Together these data imply a prominent role for the CD28-
CD80/86 system in regulating multiple pro-inflammatory cyto-
kines in the innate immune response.
While CD28 is capable of activating both CD80 and CD86, the
relative contribution of the interaction and differential effect of
these in vivo has been less well defined. The finding of improved
overall survival in CD80
2/2 and not CD86
2/2 mice implies
CD80 is the dominant receptor for regulating lethality in the
innate immune response in the early stages of CLP. This is
corroborated by the relative attenuation in IL-6 in CD80
2/2 vs.
CD86
2/2 mice and is consistent with the known ability of CD28
to regulate IL-6 production from dendritic cells in a CD80
dependent manner [14]. Interestingly, recent studies suggest
CD86, not CD80, plays a dominant role in mediating graft vs.
host disease and abdominal abscess formation [17,19,20]. The
reasons for these contrasting results are likely due to the source of
CD28 and the chronicity of inflammation. In those model systems,
there is a much more prominent role for CD4
+ T-cells, as opposed
to PMNs or soluble CD28 as observed in the early phases of sepsis.
Future studies are required to determine the interaction between
the cellular source of CD28 and predilection for CD80 vs. CD86
activity. Finally, the improved survival with anti-CD80 as opposed
to anti-CD86 confirms the results obtained with the knockout mice
and the ability of anti-CD80 to rescue mice when given after the
onset of sepsis suggests this is a potential therapeutic target as well.
The ability of CD80 to regulate inflammation can be in part
explained by its known ability to regulate the induction of NF-kB
in response to CD28 engagement. The NF-kB signaling complex
contains numerous adapter molecules which serve to both
stimulate and repress NF-kB signaling. IRAK-M is a well
described repressor of NF-kB signaling and successful induction
of pro-inflammatory signals requires loss of IRAK-M from the NF-
kB signalsome [26]. We now show that IRAK-M is directly
associated with CD80 and CD86 and that stimulation of
Figure 5. Differential Regulation of CD80 and CD86 in human sepsis. Patients with sepsis (n=31) had blood drawn within 24 hrs of ICU
admission. Samples analyzed by flow cytometry and plasma underwent cytokine analysis. Panel A-CD14
+ monocytes expression of CD80 in subjects
with (n=20) or without (N=10) septic shock. Panel B- Correlation between CD14
+ monocytes expression of CD80 and SOFA Score. Panel C- CD14
+
monocytes expression of CD86 in survivors (N=24) and non-survivors (N=6). Panel D- Correlation between CD14
+ monocytes expression of CD86
and ICU Free days. Panel E-CD14
+ monocytes expression of CD86 in subjects with (n=16) or without (N=14) bacteremia on presentation. Panels F
and G— Correlation between CD14
+ monocytes expression of CD86 and IL-6 (Panel F) and IL-10 (Panel G).
doi:10.1371/journal.pone.0006600.g005
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association with CD80, providing one potential mechanism to
explain the preferential ability of CD80 to regulate multiple
inflammatory cytokines. Further studies are required to ascertain
whether this is specific for the presence and source of CD28
(PMNs vs. T-cells), explaining the predilection for CD80 in innate
immunity while CD86 appears more prominent in the adaptive
immune response.
Another potential reason for the prominent effect for CD80 in
innate immunity, centers on the differential expression of CD80
and CD86 in sepsis. Our group and others have previously
demonstrated that sepsis is associated with marked an increase in
CD80 expression and a loss of constitutively expressed CD86 in
mice [18]. We now extend these observations to humans. Similar
to mice, humans with sepsis exhibit a loss of CD86 and
upregulation of CD80 on circulating monocytes. A prominent
role for CD80 in regulating lethal inflammation is supported by a
direct correlation between CD80 levels and severity of illness
(SOFA score) and presence of shock. Of even greater interest was
the inverse correlation of CD86 and severity of illness, with loss of
CD86 being associated with mortality, a reduction in ICU free
days and increased likelihood of shock. Further, the negative
association of CD86 with circulating levels of IL-10 and IL-6
suggest a potential direct anti-inflammatory role for CD86 in vivo.
However, the mechanism of CD86 loss remains incompletely
understood.
While our data provide strong evidence for a predominant role
for CD80 in regulation of lethal inflammation in sepsis, the role for
CD86 remains conflicted. Overall, CD86 appears to exert a
protective role, especially in the context of CD80 inhibition. This
is supported by the antagonistic effects of CD86 blockade/deletion
on survival in the setting of CD80 blockade. A potentially
beneficial/protective role for CD86 is further supported by our
human observations that persistence of CD86 expression is
associated with improved outcome. This finding is consistent with
a prior study showing reduced levels of CD86 mRNA in lethal
pediatric septic shock [27]. However, the modest survival benefit
associated with isolated CD86 blockade/deletion suggests that
some of these protective effects may be modulated by CD80 as
well. The reason for the predilection of CD80 for lethality and
CD86 for protection may lie in their relative affinities and binding
kinetics for their ligands, CD28 and CTLA4, with CD80 having a
relative higher affinity for CTLA4 [15,28,29,30]. Thus we cannot
discount a potentially protective role for a CTLA4-CD86
interaction which is unmasked by the absence of CD80 in our
system. This is a distinct possibility given the ability of CTLA4 to
both inhibit CD28 engagement as well as direct induce signaling,
including induction of tryptophan catabolism [16]. Investigators
have also described a CD28/CTLA4 independent ligand for
CD86, which may also modulate our system both signaling via the
receptor and ligand [31]. Addressing both of these possibilities will
be the subject of further studies. Finally, it is highly probable, that
the role of CD86 may indeed be tissue compartment specific. In
our previous study, we noticed differential regulation of CD86 in
blood (down regulation) and peritoneal lavage (upregulation) [18].
This most likely explains the differential cytokine response,
especially IL-10, between these differing compartments. However,
we are still unable to provide a mechanism for this differential
compartment specific regulation.
However, there are many important limitations to our study.
Most notably is the use of a highly lethal form of polymicrobial
sepsis in our murine model. It is well established that there are
multiple phases to the immune response in sepsis, with the early
phases dominated by massive pro-inflammatory cytokine produc-
tion, and the latter phase by immunoparalysis [2,32]. It is likely,
that during the transition to these latter stages, a more prominent
role for CD86 could be observed. In addition, the mechanism for
loss of CD86 expression also remains incompletely understood.
Whether this results in a true loss of expression or recruitment of
additional low expressing CD86 monocytes from the bone marrow
is also unclear. Future studies will be required to address these
questions. Finally, while our data now suggest IRAK-M may be
capable of differentially regulating CD80 and CD86 mediated
cellular activation, there are still multiple limitations to this data.
Most notably, is we can not explain the reason for the differential
affinity for CD80 and CD86 for IRAK-M under resting or
stimulated conditions. Understanding the reasons for this and the
true biological significance of this association will be the subject of
future studies detailing all members of the NF-kB signaling
complex.
In conclusion, we document a pivotal role for CD28-CD80
interaction in regulating the lethality of the acute phases of sepsis
and septic shock. This occurs predominantly through the
interaction between CD80 and CD28. These data suggest that
any future therapies targeting this system in sepsis be directed
specifically at CD80.
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